Liver Cancer Screening

Ultrasound and AFP monitoring for early liver cancer detection

Hepatocellular carcinoma (primary liver cancer) predominantly develops in livers already affected by cirrhosis or chronic hepatitis B or C. Regular 6-monthly surveillance in at-risk patients significantly improves the chance of detecting cancer at a stage where curative treatment is possible.

Surveillance combines abdominal ultrasound with serum AFP (alpha-fetoprotein) measurement every 6 months. Any suspicious lesion identified triggers immediate advanced imaging (CT or MRI) for characterisation.

Key Benefits

Evidence-based 6-monthly screening protocol for at-risk patients
Combines ultrasound and blood markers for comprehensive surveillance
Early detection when curative treatment remains possible
Coordinated pathway with hepatology and oncology when needed

Is This Treatment Right For You?

Patients with liver cirrhosis of any cause
Those with chronic hepatitis B or C infection
Patients with non-alcoholic steatohepatitis (NASH) progressing to cirrhosis

What to Expect

Baseline Assessment

Liver function, hepatitis status and ultrasound at enrolment.

6-Monthly Surveillance

Ultrasound and AFP every 6 months.

Alert Protocol

Any new lesion or AFP rise triggers immediate advanced imaging.

Multidisciplinary Review

Suspicious findings reviewed by hepatology and oncology team.

Recovery & Aftercare

No recovery — surveillance is entirely non-invasive.

Frequently Asked Questions

I have hepatitis B but normal liver function — do I need screening?

Yes, in most cases — hepatitis B carries a direct hepatocellular carcinoma risk even without cirrhosis in certain groups; your specialist will advise.